Bilimsel çalışmalar

Prof. Dr. Nezih Meydan

94 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. 1.Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I, Meydan N. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. J Cancer Res Ther. 2020 Jul- Sep;16(4):737-744. doi: 10.4103/jcrt.JCRT_1404_16. PMID: 32930112.

    Kaynak: medicana.com.tr profil sayfası

  2. 2.Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer. 2020 Oct;148:48-54. doi:10.1016/ j.lungcan. 2020.07.022. Epub 2020 Jul 27. PMID: 32799090.

    Kaynak: medicana.com.tr profil sayfası

  3. 3.Benekli M, Gumus M, Ozkan M, Dane F, Elkiran ET, Cicin I, Sevinc A, Aliustaoglu M, Isikdogan A, Meydan N, Oksuzoglu B, Ozyilkan O, Artac M, Ozdemir F, Kilickap S. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. J Oncol Pharm Pract. 2020 Oct 13:1078155220963535. doi: 10.1177/1078155220963535. Epub ahead of print. PMID: 33050804.

    Kaynak: medicana.com.tr profil sayfası

  4. 4.Yersal Ö, Kaplan MA, Işikdoğan A, Özdemir N, Aliustaoğlu M, Barutca S, Erdoğdu Hİ, Meydan N. Molecular subtypes are prognostic for N3 breast cancer patients in the modern therapeutic era. Mol Clin Oncol. 2019 Jan;10(1):180-184. doi: 10.3892/mco.2018.1771. Epub 2018 Nov 19. PMID: 30655995; PMCID: PMC6313943.

    Kaynak: medicana.com.tr profil sayfası

  5. 5.Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I, Meydan N. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma. J Cancer Res Ther. 2018 Dec;14(Supplement):S1201-S1208. doi: 10.4103/jcrt.JCRT_1404_16. PMID: 30539871.

    Kaynak: medicana.com.tr profil sayfası

  6. 6.Yersal Ö, Eryilmaz U, Akdam H, Meydan N, Barutca S. Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens. Cardiol Res Pract. 2018 May 2;2018:5352914. doi: 10.1155/2018/5352914. PMID: 29854434; PMCID: PMC5954934.

    Kaynak: medicana.com.tr profil sayfası

  7. 7.Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, Menekse S, Kocar M, Sen CA, Ordu C, Goksel G, Meydan N, Barutca S; Turkish Descriptive Oncological Researches Group. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2018 Mar;12(3):922-929. doi: 10.1111/crj.12605. Epub 2017 Jan 6. PMID: 28026133.

    Kaynak: medicana.com.tr profil sayfası

  8. 8.Aykan NF, Yalçın S, Turhal NS, Özdoğan M, Demir G, Özkan M, Yaren A, Camcı C, Akbulut H, Artaç M, Meydan N, Uygun K, Işıkdoğan A, Ünsal D, Özyılkan Ö, Arıcan A, Seyrek E, Tekin SB, Manavoğlu O, Özet A, Elkıran T, Dişçi R. Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial). Turk J Gastroenterol. 2015 Mar;26(2):145-53. doi: 10.5152/tjg.2015.5685. PMID: 25835113.

    Kaynak: medicana.com.tr profil sayfası

  9. 9.Tanriverdi O, Avci N, Oktay E, Kalemci S, Pilanci KN, Cokmert S, Menekse S, Kocar M, Sen CA, Akman T, Ordu C, Goksel G, Meydan N, Barutca S. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group. Asian Pac J Cancer Prev. 2015;16(14):5971-6. doi: 10.7314/apjcp.2015.16.14.5971. PMID: 26320482.

    Kaynak: medicana.com.tr profil sayfası

  10. 10.Tanriverdi O, Meydan N, Barutca S. Reconsideration of clinical and histopathological prognostic factors in breast cancer patients: a single center experience. Asian Pac J Cancer Prev. 2014;15(2):807-12. doi: 10.7314/apjcp.2014.15.2.807. PMID: 24568500.

    Kaynak: medicana.com.tr profil sayfası

  11. 11.Tanriverdi O, Kaytan-Saglam E, Ulger S, Bayoglu IV, Turker I, Ozturk-Topcu T, Cokmert S, Turhal S, Oktay E, Karabulut B, Kilic D, Kucukzeybek Y, Oksuzoglu B, Meydan N, Kaya V, Akman T, Ibis K, Saynak M, Sen CA, Uysal-Sonmez O, Pilancı KN, Demir G, Saglam S, Kocar M, Menekse S, Goksel G, Yapar-Taskoylu B, Yaren A, Uyeturk U, Avci N, Denizli B, Ilis-Temiz E. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG). Med Oncol. 2014 Sep;31(9):152. doi: 10.1007/s12032-014-0152-z. Epub 2014 Aug 10. PMID: 25108599.

    Kaynak: medicana.com.tr profil sayfası

  12. 12.Tanriverdi O, Cokmert S, Oktay E, Pilanci KN, Menekse S, Kocar M, Sen CA, Avci N, Akman T, Ordu C, Goksel G, Meydan N. Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group. Med Oncol. 2014 Oct;31(10):217. doi: 10.1007/s12032-014-0217-z. Epub 2014 Sep 13. PMID: 25216865.

    Kaynak: medicana.com.tr profil sayfası

  13. 13.Varol U, Oktay E, Yildirim M, Surmeli ZG, Dirican A, Meydan N, Karaca B, Karabulut B, Uslu R. Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first-line treatment of metastatic colorectal cancer. Mol Clin Oncol. 2014 Jan;2(1):166-170. doi: 10.3892/mco.2013.212. Epub 2013 Nov 12. PMID: 24649328; PMCID: PMC3915705.

    Kaynak: medicana.com.tr profil sayfası

  14. 14.Tanriverdi O, Meydan N, Barutca S. Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study. Med Oncol. 2012 Dec;29(5):3265-71. doi: 10.1007/s12032-012-0291-z. Epub 2012 Jun 30. PMID: 22752572.

    Kaynak: medicana.com.tr profil sayfası

  15. Somali I, Meydan N, Tarhan MO, Oztop I, Alacacioglu A, Yilmaz U. Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients. J BUON, Jul-Sep;14(3):429-33. (2009) PubMed PMID: 19810134.

    Kaynak: medicana.com.tr profil sayfası

  16. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy, 55(3):155-60. (2009) PubMed PMID: 19390188.

    Kaynak: medicana.com.tr profil sayfası

  17. Meteoglu I, Meydan N, Erkus M. Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy. J Exp Clin Cancer Res, Nov 12;27:69. (2008) PubMed PMID: 19014499.

    Kaynak: medicana.com.tr profil sayfası

  18. Meteoglu I, Erdogdu IH, Meydan N, Erkus M, Barutca S. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res. Oct, 19;27: 53. (2008) PubMed PMID: 18928570; PubMed PMCID: PMC2577088.

    Kaynak: medicana.com.tr profil sayfası

  19. Erkus M, Meteoglu I, Culhaci N, Meydan N, Erdogdu I. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast? Saudi Med J, Sep; 27 (9): 1329-33. (2006) PubMed PMID: 16951768.

    Kaynak: medicana.com.tr profil sayfası

  20. Meydan N., Kundak I., Yavuzsen T., Oztop I., Barutca S., Yilmaz U., Alakavuklar MN, “Cardiotoxicity of deGramont’s regimen: Incidence, clinical characteristics and long-term follow-up,” Japanese Journal of Clinical Oncology, 35, 265–270 (2005)

    Kaynak: medicana.com.tr profil sayfası

  21. Ceyhan C., Meydan N., Barutca S., Tekten T., Onbasili AO, Ozturk B., Unal S., “Ultrasound tissue characterization by integrated backscatter for analyzing fluorouracil induced myocardial damage,” Echocardiography-A Journal of Cardiovascular Ultrasound and Allied Techniques, 22, 233-238 (2005)

    Kaynak: medicana.com.tr profil sayfası

  22. Dikicioglu E., Barutca S., Meydan N., Meteoglu I., “Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes,” International Journal of Clinical Practice, 59, 1039-1044 (2005)

    Kaynak: medicana.com.tr profil sayfası

  23. Barutca S., Meydan N., Akar H., Yavasoglu I., Kadikoylu G., Bolaman Z., “Efficacy and tolerability of amifostine in elderly cancer patients,” Current Therapeutic Research-Clinical and Experimental, 65, 113-124 (2004)

    Kaynak: medicana.com.tr profil sayfası

  24. Ceyhan C., Meydan N., Barutca S., Tekten T., Onbasili AO., Ozturk B., Unal S., Bayrak I., “Influence of high dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion,” Journal of Clinical Pharmacy and Therapeutics, 29, 267-271 (2004)

    Kaynak: medicana.com.tr profil sayfası

  25. Barutca S., Ceyhan C., Meydan N., Ozturk B., Tekten T., Onbasili A., Kadikoylu G., Bolaman Z., “A new perspective on cardiotoxicity of 5-fluorouracil: A novel research tool; cardiac ultrasonic integrated backscatter analysis indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil (HDLV5FU) regimen,” Chemotherapy,50, 113-118 (2004)

    Kaynak: medicana.com.tr profil sayfası

  26. Meydan N., Barutca S., Caliskan S., Camsari T., “Urinary stone disease in diabetes mellitus,” Scandinavian Journal of Urology and Nephrology, 37, 64-70 (2003)

    Kaynak: medicana.com.tr profil sayfası

  27. Tanriverdi O, Meydan N, Barutca S, Ozsan N, Gurel D, Veral A. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma. Jpn J Clin Oncol. 2013 May;43(5):563-8. doi: 10.1093/jjco/hyt031. Epub 2013 Mar 8. PMID: 23475537.

    Kaynak: medicana.com.tr profil sayfası

  28. Oktay E, Yersal O, Meydan N, Sağıroğlu M, Uyanık O, Barutca S. Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation. Case Rep Oncol Med. 2013;2013:234391. doi: 10.1155/2013/234391. Epub 2013 Sep 26. PMID: 24191208; PMCID: PMC3804136.

    Kaynak: medicana.com.tr profil sayfası

  29. Tanriverdi O, Meydan N, Barutca S, Kadikoylu G, Sargin G, Tataroglu C, Culhaci N. Cutaneous metastasis of gallbladder adenocarcinoma in a patient with chronic lymphocytic leukemia: a case report and review of the literature. Ann Dermatol. 2013 Feb;25(1):99-103. doi: 10.5021/ad.2013.25.1.99. Epub 2013 Feb 14. PMID: 23467457; PMCID: PMC3582938.

    Kaynak: medicana.com.tr profil sayfası

  30. Tanriverdi O, Barutca S, Meydan N. Relapse with isolated peritoneal metastasis in lung adenocarcinoma: case report and review of the literature. Contemp Oncol (Pozn). 2012;16(6):586-9. doi: 10.5114/wo.2012.32495. Epub 2013 Jan 4. PMID: 23788949; PMCID: PMC3687476.

    Kaynak: medicana.com.tr profil sayfası

  31. Tanriverdi O, Unubol M, Taskin F, Meydan N, Sargin G, Guney E, Barutca S. Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review. J Oncol Pharm Pract. 2012 Jun;18(2):303-10. doi: 10.1177/1078155211424629. Epub 2011 Oct 18. PMID: 22009701.

    Kaynak: medicana.com.tr profil sayfası

  32. Tanriverdi Ö., Meydan N., Barutca S., Sargn G., Small intestine-derived gastrointestinal stromal tumour diagnosed synchronously with colon adenocarcinoma: a case report and review of the literature, Współcz Onkol, 15 (3): 175–179, (2011).

    Kaynak: medicana.com.tr profil sayfası

  33. Kadikoylu G, Barutca S, Tataroglu C, Kafkas S, Erpek H, Meydan N, Yavasoglu I, Bolaman Z. Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman. Transfus Apher Sci, Feb;42(1):39-42. Epub 2009 Nov 17. (2010)

    Kaynak: medicana.com.tr profil sayfası

  34. Kadikoylu G, Yavasoglu I, Barutca S, Meydan N, Bolaman Z. Chronic myeloid leukemia following the treatment of rectal adenocarcinoma. Med Oncol. 2008;25(4):467-70. (2008)

    Kaynak: medicana.com.tr profil sayfası

  35. Meydan N., Barutca S., Guney E., Boylu S., Savk O., Culhaci N., Ayhan M., “Brown Tumors Mimicking Bone Metastases,” J Natl Med Assoc, 98, 950-953 (2006)

    Kaynak: medicana.com.tr profil sayfası

  36. Erdogan S., Barutca S., Yurekli Y., Meydan N., Koseoglu K., “Reversible metastatic visceral calcification detected by 99mTc-methylene diphosphonate bone scanning in breast cancer,” Journal of Bone and Mineral Metabolism, 23, 407-409 (2005)

    Kaynak: medicana.com.tr profil sayfası

  37. Kundak I., Oztop I., Soyturk M., Ozcan MA., Yilmaz U., Meydan N., Gorken IB., Kupelioglu A., Alakavuklar M., “Paclitaxel-carboplatin induced radiation recall colitis,” Tumori, 90(2), 256-8 (2004)

    Kaynak: medicana.com.tr profil sayfası

  38. Barutca S., Turgut M., Meydan N., Ozsunar Y., “Subthalamic nucleus tumor causing hyperphagia,” Neurologia Medico-Chirurgica (Tokyo), 43, 457-460 (2003)

    Kaynak: medicana.com.tr profil sayfası

  39. Barutca S., Kadikoylu G., Meydan N., Bolaman Z., Gokcen A., Bal F., “Two autoimmune diseases: Hashimoto’s thyroiditis and vitiligo accompanying breast cancer; A coincidence?,” Journal of BUON., 8, 177-179 (2003).

    Kaynak: medicana.com.tr profil sayfası

  40. Barutca S., Kadikoylu G., Bolaman Z., Meydan N., Yavasoglu I., “Extravasation of paclitaxel into breast tissue from central catheter port,” Supportive Care in Cancer, 10, 563-565 (2002)

    Kaynak: medicana.com.tr profil sayfası

  41. Kitap değerlendirme, makale değerlendirme, editöre mektup, özet, tartışma, vb

    Kaynak: medicana.com.tr profil sayfası

  42. Sen S., Barutca S., Meydan N., “Azygos lobe small cell carcinoma,” European Journal of Cardio-Thoracic Surgery, 26, 1041 (2004)

    Kaynak: medicana.com.tr profil sayfası

  43. Barutca S., Meydan N., Barlak A., “Prevention of interleukin-2-induced severe bronchospasm with salbutamol,” Journal of Aerosol Medicine, 16, 183-184 (2003)

    Kaynak: medicana.com.tr profil sayfası

  44. A1.2 SCI Science Citation Index-Expanded dışındaki indekslerce taranan dergilerde yayımlanan:

    Kaynak: medicana.com.tr profil sayfası

  45. Tanriverdi O, Unubol M, Taskin F, Meydan N, Sargin G, Guney E, Barutca S. Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review. J Oncol Pharm Pract, Oct 18 (2011).

    Kaynak: medicana.com.tr profil sayfası

  46. Ayvaz O, Yavasoglu I, Kadikoylu G, Meydan N, Barutca S, Bolaman Z. The development of gastric cancer in a patient with polycythemia Vera, 3P deletion, and JAK2 V617F mutation. J Gastrointest Cancer, Dec; 41(4):254-6 (2010).

    Kaynak: medicana.com.tr profil sayfası

  47. Kiylioglu N., Meydan N., Barutca S., Akyol A., “Sub-acute sensory neuronopathy as a preceeding sign of recurrence in colon carcinoma,” International Journal of Gastrointestinal Cancer, 34, 135-137 (2003).

    Kaynak: medicana.com.tr profil sayfası

  48. A1.4 Ulusal hakemli dergilerde yayımlanan makaleler:

    Kaynak: medicana.com.tr profil sayfası

  49. Çulhacı N., Meteoğlu İ., Ünal E., Özkara E., Özgün H., Meydan N., Erkuş M., Kolorektal adenomlar ve adenokarsinomlarda hücre siklusunu düzenleyen proteinlerin ve apopitozla ilgili belirteçlerin ekspresyonu. ADÜ Tıp Fakültesi Dergisi, 11(3):9–14 (2010).

    Kaynak: medicana.com.tr profil sayfası

  50. Breast cancer practice pattern study group. Treatment approches for metastatic breast cancer in Turkey. Turkish Journal of Cancer, 35 (2), 61-69, (2005)

    Kaynak: medicana.com.tr profil sayfası